Plasma biomarkers of depressive symptoms in older adults

Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
Translational Psychiatry (Impact Factor: 5.62). 02/2012; 2(1):e65. DOI: 10.1038/tp.2011.63
Source: PubMed


The pathophysiology of negative affect states in older adults is complex, and a host of central nervous system and peripheral systemic mechanisms may play primary or contributing roles. We conducted an unbiased analysis of 146 plasma analytes in a multiplex biochemical biomarker study in relation to number of depressive symptoms endorsed by 566 participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) at their baseline and 1-year assessments. Analytes that were most highly associated with depressive symptoms included hepatocyte growth factor, insulin polypeptides, pregnancy-associated plasma protein-A and vascular endothelial growth factor. Separate regression models assessed contributions of past history of psychiatric illness, antidepressant or other psychotropic medicine, apolipoprotein E genotype, body mass index, serum glucose and cerebrospinal fluid (CSF) τ and amyloid levels, and none of these values significantly attenuated the main effects of the candidate analyte levels for depressive symptoms score. Ensemble machine learning with Random Forests found good accuracy (~80%) in classifying groups with and without depressive symptoms. These data begin to identify biochemical biomarkers of depressive symptoms in older adults that may be useful in investigations of pathophysiological mechanisms of depression in aging and neurodegenerative dementias and as targets of novel treatment approaches.

Download full-text


Available from: Mitchel A Kling,
  • [Show abstract] [Hide abstract]
    ABSTRACT: Biomarkers are often measured with error due to imperfect lab conditions or temporal variability within subjects. Using an internal reliability sample of the biomarker, we develop a parametric bias-correction approach for estimating a variety of diagnostic performance measures including sensitivity, specificity, the Youden index with its associated optimal cut-point, positive and negative predictive values, and positive and negative diagnostic likelihood ratios when the biomarker is subject to measurement error. We derive the asymptotic properties of the proposed likelihood-based estimators and show that they are consistent and asymptotically normally distributed. We propose confidence intervals for these estimators and confidence bands for the receiver operating characteristic curve. We demonstrate through extensive simulations that the proposed approach removes the bias due to measurement error and outperforms the naïve approach (which ignores the measurement error) in both point and interval estimation. We also derive the asymptotic bias of naïve estimates and discuss conditions in which naïve estimates of the diagnostic measures are biased toward estimates produced when the biomarker is ineffective (i.e., when sensitivity equals 1 - specificity) or are anticonservatively biased. The proposed method has broad biomedical applications and is illustrated using a biomarker study in Alzheimer's disease. We recommend collecting an internal reliability sample during the biomarker discovery phase in order to adequately evaluate the performance of biomarkers with careful adjustment for measurement error. Copyright © 2013 John Wiley & Sons, Ltd.
    Statistics in Medicine 11/2013; 32(27). DOI:10.1002/sim.5878 · 1.83 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to characterize hepatitis C virus (HCV)-associated differences in the expression of 47 inflammatory factors and to evaluate the potential role of peripheral immune activation in HCV-associated neuropsychiatric symptoms—depression, anxiety, fatigue, and pain. An additional objective was to evaluate the role of immune factor dysregulation in the expression of specific neuropsychiatric symptoms to identify biomarkers that may be relevant to the treatment of these neuropsychiatric symptoms in adults with or without HCV. Blood samples and neuropsychiatric symptom severity scales were collected from HCV-infected adults (HCV+, n = 39) and demographically similar noninfected controls (HCV−, n = 40). Multi-analyte profile analysis was used to evaluate plasma biomarkers. Compared with HCV− controls, HCV+ adults reported significantly (P < 0.050) greater depression, anxiety, fatigue, and pain, and they were more likely to present with an increased inflammatory profile as indicated by significantly higher plasma levels of 40% (19/47) of the factors assessed (21%, after correcting for multiple comparisons). Within the HCV+ group, but not within the HCV− group, an increased inflammatory profile (indicated by the number of immune factors > the LDC) significantly correlated with depression, anxiety, and pain. Within the total sample, neuropsychiatric symptom severity was significantly predicted by protein signatures consisting of 4–10 plasma immune factors; protein signatures significantly accounted for 19–40% of the variance in depression, anxiety, fatigue, and pain. Overall, the results demonstrate that altered expression of a network of plasma immune factors contributes to neuropsychiatric symptom severity. These findings offer new biomarkers to potentially facilitate pharmacotherapeutic development and to increase our understanding of the molecular pathways associated with neuropsychiatric symptoms in adults with or without HCV.
    Brain and Behavior 03/2014; 4(2):123-42. DOI:10.1002/brb3.200 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Blood has been the object of a search for biomarkers for psychiatric disorders since long before the advent of proteomics. A series of investigations have been conducted on serum or plasma, either by focusing on protein candidates such as cytokines or brain-derived neurotrophic factor (BDNF) or by testing multiple candidates simultaneously. Notwithstanding the amount of suggestive evidence for depression, no real biomarker application has made an impact on clinical practice so far. Relatively consistent findings have been obtained for a few candidate proteins, such as BDNF - which, however, appears to be nonspecifically dysregulated across many neuropsychiatric conditions. Combination of biomarkers and the broader picture represented by proteomic profiles are providing a better chance to divide the disorder into subtypes and gain specificity versus other diseases. Most efforts have focused on the identification of proteomic signatures able to discriminate patients from controls, even leading to the proposal of diagnostic tests for mental disorders; however, no major attempts have been made to fulfill the clinical need for signatures able to predict response to antidepressants. In this review, the most interesting findings obtained by searching serum or plasma by proteomic approaches are put into the context of their potential clinical application, highlighting potential pitfalls and opportunities. New directions in proteomic biomarker efforts beyond cross-sectional studies in case-control collections as defined by diagnosis are advocated, and the need for an effective integration of biomarkers at different levels is emphasized. Capturing the contribution of genetic variability to protein expression, and ultimately integrating this information with imaging measures of brain structure and function, will open new avenues for the discovery of mechanisms and circuits involved in disease pathophysiology and drug response.
    05/2014; 29:81-81. DOI:10.1159/10.1159/000358178
Show more